Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
1.650
-0.080 (-4.62%)
At close: Sep 18, 2026, 4:00 PM EDT
1.630
-0.020 (-1.21%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2026, Radiopharm Theranostics had annual revenue of 13.50M AUD with 7.91% growth. Radiopharm Theranostics had revenue of 7.30M in the half year ending June 30, 2026.
Revenue (ttm)
13.50M AUD
Revenue Growth
+7.91%
P/S Ratio
2.64
Revenue / Employee
964,448 AUD
Employees
14
Market Cap
24.67M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 13.50M | 990.09K | 7.91% |
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
RADX News
- 4 days ago - Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up - Nasdaq
- 4 days ago - Radiopharm Theranostics Registration statement: Registration filing - Filings
- 9 days ago - Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer - Nasdaq
- 9 days ago - Radiopharm announces data from imaging trial of RAD 301 - TheFly
- 9 days ago - Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 23 days ago - Radiopharm Doses First Patient In Second Cohort Of Phase 1/2a RV-01 Trial - Nasdaq
- 23 days ago - Radiopharm doses first patient in second cohort of RV-01 trial - TheFly
- 23 days ago - Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors - GlobeNewsWire